Corticosteroids (Prednisone / IV Methylprednisolone)
Oral or IV steroids that broadly suppress immune activity — effective but with long-term trade-offs
Route
Oral (prednisone) or intravenous (methylprednisolone)
Frequency
Daily oral or monthly IV pulse
Setting
Outpatient / home (oral); infusion center (IV pulse)
FDA Status
Used off-label for CIDP per EAN/PNS 2021 guideline
Educational use only. This page explains how Corticosteroids works based on clinical guidelines and trial data. It cannot replace your neurologist. All treatment decisions must be made with your medical team.
How Corticosteroids Works
Corticosteroids (prednisone taken orally, or methylprednisolone given intravenously) suppress the immune system broadly by reducing inflammation throughout the body. In CIDP, this dampens the autoimmune attack on peripheral nerve myelin, though through non-selective immune suppression rather than the targeted mechanisms of IVIG or Vyvgart Hytrulo.
- •Bind to glucocorticoid receptors inside immune cells, blocking production of pro-inflammatory cytokines (IL-1, IL-6, TNF-α)
- •Suppress T-lymphocyte proliferation and activation, reducing the immune attack on peripheral nerves
- •Inhibit B-cell antibody production, reducing levels of pathogenic anti-myelin antibodies
- •Decrease permeability of the blood-nerve barrier, limiting immune cell infiltration of the peripheral nervous system
- •Two common protocols: (1) daily oral prednisone starting at 60–80 mg/day, gradually tapered over months to the lowest effective dose; (2) monthly IV methylprednisolone pulse — 500–1000 mg IV for 1–3 consecutive days, repeated monthly
- •Pulse IV methylprednisolone has a better side-effect profile for long-term use than continuous oral prednisone because the systemic exposure is intermittent
Clinical Evidence
Approximately 60–70% of patients with typical CIDP respond to corticosteroids. They carry Level A evidence in the EAN/PNS 2021 guideline. However, there is a critical exception: corticosteroids are NOT recommended for pure motor CIDP and may paradoxically worsen weakness in that variant.
| Metric | Value | Source |
|---|---|---|
| Response rate (typical CIDP) | ~60–70% | EAN/PNS 2021 guideline |
| Evidence level | Level A | EAN/PNS 2021 guideline |
| Use in pure motor CIDP | ⚠️ NOT recommended — may worsen | EAN/PNS 2021 guideline |
| Time to response | Weeks to months | EAN/PNS 2021 |
| Starting oral dose (typical) | 60–80 mg/day prednisone | Standard protocol |
| IV pulse dose (typical) | 500–1000 mg methylprednisolone monthly | Standard protocol |
⚠️ Pure motor CIDP warning: The EAN/PNS 2021 guideline specifically states that corticosteroids should be avoided in pure motor CIDP variants. Clinical experience and some case series suggest steroids may worsen weakness in this subtype, possibly by increasing the abnormal immunoglobulin response. If you have predominantly motor symptoms with little or no sensory involvement, ask your neurologist whether you have pure motor CIDP before starting steroids.
Steroid-sparing agents (azathioprine, mycophenolate mofetil, cyclosporine) are often added after initial stabilization to allow the steroid dose to be reduced, minimizing long-term side effects while maintaining disease control.
Side Effects
Common
- •Weight gain and fluid retention
- •Increased appetite
- •Mood changes: irritability, anxiety, or euphoria ("steroid mood")
- •Insomnia
- •Elevated blood sugar (especially problematic in diabetics)
- •Acne and skin changes
- •Easy bruising
Serious (less common)
- •Osteoporosis: significant bone density loss with long-term use; calcium, vitamin D, and bisphosphonate supplementation recommended
- •Cataracts: posterior subcapsular cataracts develop with chronic steroid use
- •Diabetes / hyperglycemia: may unmask or worsen type 2 diabetes
- •Hypertension: sodium retention raises blood pressure
- •Avascular necrosis of the hip: painful and potentially debilitating; more common with high doses
- •Adrenal suppression: abrupt discontinuation after prolonged use can cause adrenal crisis — always taper slowly
- •Increased infection risk: impaired immune function increases susceptibility to bacterial, viral, and fungal infections
- •Cushingoid features: moon face, buffalo hump, central weight gain with chronic high-dose use
Long-term side effects are the primary reason corticosteroids are used at the lowest effective dose and often in combination with steroid-sparing immunosuppressants. Patients on chronic corticosteroids should receive bone protection (1200 mg calcium + 800 IU vitamin D daily; consider bisphosphonate if on ≥5 mg prednisone for ≥3 months). Do NOT stop corticosteroids abruptly after more than a few weeks of use — adrenal suppression requires a gradual taper.
Pros & Cons
Advantages
- ✓Inexpensive and universally available — no prior authorization typically required
- ✓Oral option — no infusion center visits (for daily prednisone)
- ✓Well-understood safety and monitoring profile after decades of use
- ✓Effective for typical, sensory-predominant CIDP
- ✓Can be combined with steroid-sparing agents to reduce long-term dose
- ✓Monthly IV pulse option has better side-effect profile than daily oral
Drawbacks
- –⚠️ Contraindicated in pure motor CIDP — may worsen weakness
- –Significant long-term side effect burden (osteoporosis, cataracts, diabetes, hypertension)
- –Requires slow tapering — cannot stop abruptly
- –Slower onset than IVIG or plasma exchange
- –Adrenal suppression risk with chronic use
- –Mood and sleep disturbance affects quality of life
Insurance & Access
- →Generic prednisone costs pennies per pill — typically covered without prior authorization
- →IV methylprednisolone infusions require prior authorization but are generally approved
- →Steroid-sparing agents (azathioprine, mycophenolate mofetil) are inexpensive generics and usually covered
- →No patient assistance programs needed for generic corticosteroids given low cost
- →If an insurer requires corticosteroid step therapy before approving IVIG, document pure motor CIDP (if applicable) or any contraindications as grounds for waiver
Have a question about Corticosteroids?
Ask the AI assistant for more detail — dosing questions, wearing-off, insurance appeals, how Corticosteroids compares to other options, and more.
Ask the AI →Other CIDP Treatments
IVIG
The most widely used first-line treatment for CIDP, with Level A evidence
Vyvgart Hytrulo
First FDA-approved FcRn inhibitor for CIDP — a 30-second weekly injection at home
SCIg
Weekly home injections that eliminate infusion center visits and the wearing-off effect
Plasma Exchange
A fast-acting procedure that physically removes harmful antibodies from the blood
Sources
- van den Bergh PYK, et al. EAN/PNS Guideline on CIDP. Eur J Neurol. 2021;28(11):3556–3583.
- Mehndiratta MM, et al. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2015.
- Eftimov F, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013.